Ovarian transposition and cervical cancer

Alexandros Laios, Sara Duarte Portela, Argyro Papadopoulou, Ioannis D Gallos, Mohamed Otify, Thomas Ind

Research output: Contribution to journalReview articlepeer-review

1 Citation (Scopus)


Cervical cancer is the fourth most common female malignancy worldwide. As the focus of treatment is shifting towards balancing oncological outcomes with reproductive benefit, women are becoming increasingly aware of their fertility options. Cervical cancer is one of the primary malignancies where transposition of the ovaries may be indicated. Ovarian transposition should be performed in pre-menopausal women, undergoing pelvic irradiation to preserve ovarian function and prevent early menopause. The review discusses the available literature and synthesises a concise summary for gynaecologic oncology surgeons to counsel affected women. The paradoxical controversy, leading to its under use is acknowledged, due to the scarcity of published data with regard to functional outcomes, and the lack of clinical trials. In cervical cancer, ovarian transposition remains a safe fertility preservation (FP) option, which is associated with high ovarian function preservation, an acceptable rate of ovarian cysts and a negligible risk for metastases in the transposed ovaries.

Original languageEnglish
Pages (from-to)37-53
JournalBest Practice & Research: Clinical Obstetrics & Gynaecology
Early online date26 Feb 2021
Publication statusE-pub ahead of print - 26 Feb 2021


  • Ovarian transposition
  • Cervical cancer
  • Fertility preservation
  • Ovarian function
  • Pelvic radiotherapy

ASJC Scopus subject areas

  • Obstetrics and Gynaecology


Dive into the research topics of 'Ovarian transposition and cervical cancer'. Together they form a unique fingerprint.

Cite this